Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated Chinese and Western medicine for long COVID sequelae
ChiCTR2400083511Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Qingjin Huatan Decoction, codeine + platycodon, ketotifen and methoxyphenamine hydrochloride in post-COVID syndrome (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: TCM symptom and degree score. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
Qingjin Huatan Decoctioncodeine + platycodonketotifenmethoxyphenamine hydrochloride
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on ChiCTR2400083511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083511.